Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCM for Radiation-induced Oral Mucositis in Head and Neck Cancer
NCT07282483Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2026
- Primary completion
- Aug 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Qingying oral liquid and modified dahuang huanglian xiexin mouthwash in oral mucositis (OM) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence rate of severe oral mucositis (RTOG grade >= 3) at 14.5 weeks. Started Mar 2026; status: recruiting.
02
Drugs
Qingying oral liquidmodified dahuang huanglian xiexin mouthwash
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT07282483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282483.